UCB Pharma
Quick facts
Marketed products
- Certolizumab Pegol (CZP) · Immunology
Certolizumab pegol is a TNF-alpha inhibitor that binds to and neutralizes tumor necrosis factor-alpha, reducing inflammatory signaling. - Cetirizine drops · Immunology / Allergy
Cetirizine is a selective H1-receptor antagonist that blocks histamine binding to H1 receptors on mast cells and basophils, preventing allergic cascade activation. - Cetirizine tablets · Immunology / Allergy
Cetirizine is a selective H1-receptor antagonist that blocks histamine binding to H1 receptors on cells, reducing allergic symptoms. - Kemstro · Other
- Levetiracetam (Keppra) · Neurology
Levetiracetam reduces seizure activity by binding to synaptic vesicle protein SV2A and modulating neurotransmitter release. - Levocetirizine (drug) · Allergy/Immunology
Levocetirizine is a selective H1-receptor antagonist that blocks histamine binding to H1 receptors on mast cells and basophils, preventing allergic cascade activation. - Levocetirizine oral solution · Allergy/Immunology
Levocetirizine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses. - Methylphenidate Extended Release Capsules · Neurology; Psychiatry
Methylphenidate is a central nervous system stimulant that increases dopamine and norepinephrine activity in the brain by blocking their reuptake at the presynaptic neuron. - Neupro® · Neurology
Neupro is a dopamine agonist that stimulates dopamine receptors in the brain to restore dopamine signaling in patients with Parkinson's disease and restless legs syndrome. - Niravam · Other
- SSRI/SNRI · Psychiatry/Neurology
SSRIs and SNRIs increase serotonin (and norepinephrine for SNRIs) in the brain by blocking their reuptake from the synaptic cleft, thereby enhancing mood regulation and emotional processing.
Phase 3 pipeline
- Alprazolam orally disintegrating tablets · Psychiatry/Neurology
Alprazolam is a benzodiazepine that enhances the inhibitory effects of GABA at the GABA-A receptor, reducing neuronal excitability and producing anxiolytic and sedative effects. - Brivaracetam bolus · Neurology
Brivaracetam is a selective synaptic vesicle protein 2A (SV2A) ligand that modulates neurotransmitter release to reduce seizure activity. - Brivaracetam infusion · Neurology
Brivaracetam binds to synaptic vesicle protein 2A (SV2A) to reduce neuronal excitability and prevent seizures. - Brivaracetam (ucb 34714) · Neurology
Brivaracetam binds to synaptic vesicle protein 2A (SV2A) to reduce neuronal excitability and prevent seizures. - Certolizumab pegol (CDP870) · Immunology
Certolizumab pegol is a TNF-alpha inhibitor that binds to and neutralizes tumor necrosis factor-alpha, reducing inflammatory signaling. - Keppra® extended release formulation - XR · Neurology
Levetiracetam binds to synaptic vesicle protein 2A (SV2A) to reduce neuronal excitability and prevent seizure propagation. - Keppra XR (Levetiracetam XR) · Neurology
Levetiracetam reduces seizure activity by binding to synaptic vesicle protein SV2A and modulating neurotransmitter release. - Placebo-Cetirizine · Immunology / Allergy
Cetirizine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses in the central and peripheral nervous systems. - Placebo-Levocetirizine · Allergy/Immunology
Levocetirizine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses. - Placebo + Methotrexate (MTX) · Immunology / Rheumatology
Methotrexate inhibits dihydrofolate reductase to suppress DNA synthesis and reduce inflammatory immune cell proliferation. - Placebo to Pentoxifylline oral · Cardiovascular / Vascular disease
Pentoxifylline improves blood flow and reduces blood viscosity by increasing red blood cell flexibility and decreasing platelet aggregation. - SPM 927 · Neurology
SPM 927 is a selective T-type calcium channel blocker that reduces neuronal excitability and seizure activity. - SPM 929 · Psychiatry
SPM 929 is a selective serotonin reuptake inhibitor (SSRI) that works by increasing the levels of serotonin in the brain.
Phase 2 pipeline
- CDP6038
- Levocetirizine tablets · Respiratory
Selective histamine H1 receptor antagonist - Rotigotine Nasal Spray
- Rotigotine patch
- SPM 936
Phase 1 pipeline
- CDP 6038 SC
- CDP7657
- Moxifloxacin infusion
- Reglan ODT
- Rotigotine, Period 1
- Rotigotine, Period 2
- Rotigotine PR 2.1.4
- Rotigotine PR 2.2.1
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: